Trinity Biotech plc (TRIB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Trinity Biotech plc (TRIB) is down 26.4% since the beginning of the year. At $1 per share, TRIB is trading 83.1% below its 52-week high of $3. Investors who bought $1,000 worth of TRIB shares 5 years ago would now be looking at an investment worth $41.

Trinity Biotech plc (TRIB) has returned -26.42% so far this year and 2.46% over the past 12 months. Over the last ten years, TRIB has returned -36.71% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Aug 18, 1995, TRIB's average daily return is +0.05%, while the average monthly return is +0.48%. At this rate, an investment would double in approximately 12.1 years.

Historically, 46% of months were positive and 54% were negative. The best month was Aug 2025 with a return of +112.9%, while the worst month was Oct 2016 at -48.4%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, TRIB closed higher 44% of trading days. The best single day was Aug 14, 2025 with a return of +89.1%, while the worst single day was Oct 4, 2016 at -50.3%.

Trinity Biotech plc has an annualized alpha of 6.43%, beta of 0.52, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 18, 1995.

• This stock participated in 143.66% of S&P 500 Index downside but only 48.06% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.52 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TRIB ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

Trinity Biotech plc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Trinity Biotech plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Trinity Biotech plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Trinity Biotech plc was 99.63%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Trinity Biotech plc drawdown is 99.59%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Trinity Biotech plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Trinity Biotech plc is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.